Spinal cord stimulation for diabetic foot: how China uses a global technology differently

Spinal cord stimulation (SCS) is not a new technology and it is not unique to China. Developed decades ago for chronic pain management, SCS devices are made by Medtronic, Abbott, and Boston Scientific — all Western companies. The technology is FDA-approved and used in hospitals worldwide. But here is what most patients do not know: Chinese specialist centers have taken this well-established technology and applied it to a problem Western hospitals rarely address with SCS — saving diabetic feet from amputation. This article explains the difference and what it means for patients. It is general education, not medical advice — always consult a qualified specialist.

What is spinal cord stimulation and how does it work?

A thin electrode is placed in the epidural space of the spinal canal. It delivers mild electrical pulses that modulate nerves controlling the lower limb. Two things happen simultaneously:

• Pain signals are intercepted before reaching the brain — reducing chronic ischemic pain without medication
• Sympathetic nerves are modulated, triggering release of CGRP (calcitonin gene-related peptide) — a potent vasodilator that opens microvessels in the foot, restoring blood flow to tissue that stents and bypass grafts cannot reach

It is this second effect — microvascular vasodilation — that makes SCS relevant for diabetic foot limb salvage, not just pain relief.

The gap between Western and Chinese SCS practice

In the US and Europe, SCS is primarily prescribed for chronic pain: failed back surgery syndrome, complex regional pain syndrome, and — since the 2025 FDA approval — painful diabetic neuropathy. The clinical goal is pain reduction. Wound healing and limb salvage are not part of the Western SCS conversation.

Chinese specialist centers see SCS differently. They observed that the microvascular improvement from SCS could address a specific clinical dead end: patients whose large leg arteries are open (or already treated with stents), but whose feet remain ischemic because thousands of tiny microvessels are diseased. No catheter can reach these vessels. No bypass can connect to them. These patients face amputation — not because surgery failed, but because no surgery exists for diffuse microvascular disease.

In 2026, China published the first national Expert Consensus on SCS specifically for diabetic foot, formalizing indications, surgical protocols, and follow-up standards. No equivalent guideline exists in the US or Europe.

Clinical outcomes: what does the evidence show?

Chinese multi-center studies report outcomes that Western pain-focused SCS literature does not track:

• 70%+ limb salvage rate in patients where both medication and endovascular intervention had already failed (Yao et al., 2024, 57 cases)
• 88% efficacy at 6 months in high-risk diabetic feet, with only 8% new ulcer incidence at 1 year (Qilu Hospital data)
• Significant improvement in transcutaneous oxygen pressure (TcPO₂) and ankle-brachial index at 6 and 12 months — objective measures of restored blood flow, not just subjective pain scores
• Rapid pain relief: most patients report substantial VAS score reduction within days, with improved sleep quality

These are retrospective studies from selected centers, not randomized controlled trials. The evidence is promising but still maturing. What is clear: Chinese centers are tracking limb salvage as a primary outcome of SCS, while Western centers track only pain reduction.

Cost comparison: China vs. the West

The cost difference is substantial and stems from both device pricing and healthcare system structure:

• United States: SCS device + implantation typically costs $30,000–$50,000+. Insurance coverage for DFU-related SCS (as opposed to pain indications) is limited or unavailable
• United Kingdom: SCS is available through NHS for approved pain indications, but wait times of 8–16 weeks are common. DFU limb salvage is not a standard NHS SCS indication
• China: SCS for diabetic foot has been included in medical insurance (医保) in multiple provinces. China's volume-based procurement policies have reduced neuromodulation device costs. Total cost at Chinese partner centers is typically a fraction of US pricing

For international patients, the combination of lower device costs, established DFU-specific protocols, and no waiting list makes Chinese centers a practical option — particularly for patients whose home country does not offer SCS for limb salvage at all.

Who is SCS right for?

SCS for diabetic foot addresses a specific clinical scenario — it is not a universal treatment:

• The defining indication: large vessels are open or already treated, but the foot remains ischemic because microvascular disease is too diffuse for intervention
• Refractory painful diabetic neuropathy that has not responded to medication or nerve blocks
• A trial stimulation (7–14 days with a temporary electrode) confirms response before permanent implantation — if pain does not decrease and skin temperature does not rise, permanent implant is not recommended

SCS is not appropriate when foot bones are already completely necrotic (gangrene), when severe uncontrolled infection or sepsis is present, or when large-vessel disease is the primary problem — in that case, revascularization should come first.

How SCS fits alongside other treatments

SCS is complementary to other diabetic foot interventions, not a replacement:

• Revascularization opens large arteries; SCS opens microvessels — different targets, sometimes used sequentially
• TCT (Tibial Cortex Transposition) stimulates new blood vessel growth from bone; SCS dilates existing vessels via nerve modulation — different mechanisms for overlapping patient populations
• HBOT delivers oxygen to hypoxic tissue; SCS delivers blood flow — they can be combined
• Wound care, glycemic control, and infection management remain essential regardless of whether SCS is used

The bottom line for patients

SCS is a proven, globally available technology. What differs between China and the West is not the device — it is how it is used. Chinese centers have systematized SCS as a limb-salvage tool for diabetic feet with microvascular disease, published national guidelines, accumulated high case volumes, and made it financially accessible through insurance coverage. If your diabetic foot wound is not healing because of microvascular disease — and endovascular treatment has failed or is not feasible — SCS may be worth discussing with a specialist who uses it for this specific indication.

DFU Care China coordinates evaluation for international patients considering SCS for diabetic foot limb salvage. Share your medical records and wound photos via WhatsApp for a free, confidential assessment.

This article is for educational purposes. Every patient's situation is different. The treatment options described here may not apply to all patients. Always consult a qualified medical professional about your specific situation.